Would be nice to have a par representative on here to answer...

First 75 Last

Share
Profile

Follow
Beaza79

5,237 Posts.

678

27/10/21

19:15

Post #: 57123817
Share

Originally posted by Zenox: ↑

Randomisation works in blocks e.g. blocks of 4 or 6 etc. Lets say in this case randomisation was in blocks of 6, where 3 were randomly given placebo and 3 iPPS. The ratio is 1:1, so yes we should expect 15 were given placebo and 15 iPPS. In terms of pull outs, these numbers will have to be worked in to the sensitivity analyses, although I think in this case they may just be excluded.

It is intriguing that only 30 were enrolled before 008 was halted. This was despite people still trying to register for the trial. Was the trial halted for poor recruitment, and if so, why was it halted at exactly 30 participants? To me, this appears to have been deliberate. At the time 008 was halted, PAR could've had access to results from around half of the participants. As of yesterday, PAR could've had access to day 56 results from all 30 participants.

A valid critique is, if PAR are aware of such results then why haven't they disclosed them to the market? A possible answer is, because analysis of the results are incomplete and the trial is ongoing. We know that PAR will be receiving information about these trials, what we don't know is what type of information.

Looking at the statistical analysis plan for 008, PAR does not pay a statistical penalty for looking at the results and making changes to the observation period, since the trial is exploratory in nature and the changes only apply to the secondary endpoints. These changes are essentially "a free shot on goal".

Also, if we look at the primary endpoint we can see that PAR only needs to observe a significant change in ONE biomarker for the primary endpoint to be achieved, even though ten biomarkers are specified. No type I error rate has been specified in the SAP and a restricted maximum likelihood (REML)-based mixed model for repeated measures (MMRM) approach will be used to assess the change from baseline in biomarkers in synovial fluid at Day 56.

This approach allows each biomarker to be assessed separately for the untreated/treated groups without applying a penalty for the overall number of biomarkers being assessed. In other words, it is similar to placing your chips on red at the roulette table with 10 spins in hand and you only need to land on red once to win. And if we achieve the primary endpoint then all of the secondary endpoints that reach significance are also valid.

Expand

Would be nice to have a par representative on here to answer your questions, and questions im sure others want the answer to.

PAR Price at posting: $1.89 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Superannuation Essentials: Building Wealth for Your Retirement

WTC

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

KAU

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

BTH

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 2 more messages in this thread...

First 75 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 22.5¢		Change -0.040(15.1%)		Mkt cap ! $78.80M

Open	High	Low	Value	Volume
26.5¢	26.5¢	22.0¢	$503.0K	2.101M

Buyers (Bids)

No.	Vol.	Price($)
1	10000	22.5¢

Sellers (Offers)

Price($)	Vol.	No.
23.0¢	210000	2

View Market Depth

No.	Vol.	Price($)
1	10000	0.225
3	88010	0.220
9	36830	0.215
9	68573	0.210
3	33500	0.205

Price($)	Vol.	No.
0.230	210000	2
0.250	18707	2
0.260	107580	3
0.265	58273	4
0.270	12000	1

Last trade - 16.10pm 21/10/2024 (20 minute delay)

PAR (ASX) Chart

Would be nice to have a par representative on here to answer...

Superannuation Essentials: Building Wealth for Your Retirement

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Would be nice to have a par representative on here to answer...

Top Stories

Superannuation Essentials: Building Wealth for Your Retirement

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News